论文部分内容阅读
思密达作为一种高效消化道粘膜保护剂已得到广泛应用,为探讨其对肠结核的辅助疗效,作者对30例肠结核患者辅以思密达治疗,报告如下。 1 对象和方法 1.1 对象 共观察病例60例,符合以下条件:①临床有结核中毒症状和(或)腹部症状(体征)及大便改变;②大便抗酸杆菌阳性;③大便结核菌培养阳性;④X线造影可见粘膜破坏或肠管狭窄等征象;⑤初治病例。随机分为治疗组、对照组各30例。治疗组男18例,女12例,年龄22-64岁,平均37岁;对照组男21例,女9例,年龄27-60岁,平均35.5岁。发病时间:治疗组3个月以内3例,3-6个月16例,6个月以上11例;对照组3个月以内2例,3-6个月19例,6个月以上9例。临床表现:治
Smectite as a highly effective mucosal protective agent of the digestive tract has been widely used, in order to explore its auxiliary effect on intestinal tuberculosis, the authors of 30 cases of intestinal tuberculosis patients treated with Smectite, the report is as follows. 1 objects and methods 1.1 objects were observed in 60 cases, in line with the following conditions: ① clinical symptoms of tuberculosis and / or abdominal symptoms (signs) and stool changes; ② stool acid-fast bacilli positive; ③ stool culture positive TB; ④ X Line contrast shows signs of mucosal damage or intestinal stenosis; ⑤ initial treatment cases. Randomly divided into treatment group, control group of 30 cases. Treatment group, 18 males and 12 females, aged 22-64 years, an average of 37 years; control group of 21 males and 9 females, aged 27-60 years, mean 35.5 years. Incidence: 3 cases in the treatment group within 3 months, 16 cases 3-6 months, 11 cases more than 6 months; control group 2 cases within 3 months, 3-6 months in 19 cases, 6 months or more in 9 cases . Clinical manifestations: treatment